NCT07046273View on ClinicalTrials.gov

Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

496

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2028

Study Completion Date

February 1, 2029

Conditions
Type 2 Diabetes (T2DM)
Interventions
DRUG

F027

The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.

DRUG

Ozempic®

The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.

All Listed Sponsors
lead

Shandong New Time Pharmaceutical Co., LTD

INDUSTRY